Nov 9, 2021 — 4 min read
Lunit welcomes three members with over 10 years of professional experience in biotech and scientific fields
Company also further strengthened its advisory board with two biotech and medical experts
Lunit, a leading medical AI provider, today announced it recently reinforced its team with industry and regulatory experts to accelerate its business expansion and growth in the US. New joiners include Ken Nesmith (Former CEO of Lexent Bio), Marcus Skovhus (Former Senior Director at Foundation Medicine), and Subok Park (Former Regulatory Scientist at US Food and Drug Administration (FDA)).
The company also announced Mark Germain, Managing Director at Aentib Group, and Dr. Young Kwang Chae, Medical Oncologist at Northwestern University Feinberg School of Medicine, joined as advisors to provide expert insight at Lunit's advisory board.
"It is with great honor that I welcome new members and advisors with remarkable accomplishments and expertise in the biotech industry, medicine, and regulatory affairs," said Brandon Suh, CEO of Lunit. "These are core pillars that form our business and lead its growth and we are lucky to have them join us at an exciting time as we accelerate growth and expansion in the global market."
The company welcomed three members with over 10 years of professional experience in biotech and scientific fields. They will spearhead Lunit's Oncology business, corporate development, and regulatory strategy, respectively.
Ken Nesmith, Chief Business Officer, Oncology
Ken Nesmith has been active in healthcare and life sciences as a technologist and executive for over 15 years. He was the co-founder and CEO of Lexent Bio, a leading liquid biopsy company that was acquired by Foundation Medicine (Parent company: Roche) in 2020. Prior to Lexent Bio, he built his career at many renowned companies such as Counsyl, Noom, Boston Consulting Group, and Goldman Sachs. As CBO of Oncology, Ken will oversee business opportunities for Lunit's cancer treatment solutions. "The team at Lunit shares a commitment to changing cancer detection, diagnosis, and treatment, driving advances at the intersection of AI and cancer biology," said Ken. "I'm thrilled and honored to join the executive leadership team in support of the mission at Lunit."
Marcus Skovhus, VP of Corporate Development
Marcus Skovhus is a biotech professional with 10 years of tenure across a spectrum of healthcare areas including therapeutic development, advanced diagnostic platforms and more. Most recently, he was responsible for Corporate Strategy and Portfolio Planning at Foundation Medicine (FMI). Prior to FMI, he worked as a consultant at ZS Associates in Boston after having spent 7 years in various strategy related roles within Hoffmann-La Roche's pharmaceutical division in Basel, Switzerland. At Lunit, he will develop and execute corporate strategy and M&A activities to accelerate the company's long-term growth. "Lunit's achievements in the AI space over the past years represent major milestones for the future of cancer care," said Marcus. "I am excited to join this very talented and mission driven team, and to support the future growth of the organization."
Subok Park, Director of Clinical Strategy, Radiology Medical Affairs
Subok Park is a regulatory scientist with expertise in the objective assessment of medical image quality. She has over 16 years of professional experience working at the US FDA, where she directed a research program for breast imaging assessment and shaped FDA's regulatory strategy for medical imaging device assessment. Her most recent professional experience includes the assessment of artificial intelligence/machine learning (AI/ML)-based computer-assisted software devices (CADs), as well as regulatory strategy for AI/ML software as a medical device (SaMD) beyond the scope of CAD. With this combination of regulatory and technical expertise, Subok will lead in establishing regulatory strategies for Lunit AI/ML SaMD products. "Since joining Lunit last August, I've been greatly enjoying working synergistically with highly intelligent and dedicated members of Lunit with interdisciplinary expertise for various products to market in the US," commented Subok.
Lunit also further strengthened its advisory board with two biotech and medical experts. It is known to hold a strong advisory board of industry KOLs including Dr. Eliot Siegel, Dr. Linda Moy, Dr. Khan Siddiqui, Dr. Tony Mok, Scott Schubert and more.
Mark Germain is a Managing Director at The Aentib Group, a boutique merchant banking company based in Canada. As a biotech guru active in the industry since 1991, he is known to be involved as a founder, director, chairman of the board of, and/or investor in, over twenty companies in the biotech field. Many of the companies he co-founded are publicly listed in NASDAQ, including Incyte Corporation, Neurocrine Biosciences, Inc., Alexion Pharmaceuticals, Inc., and ChromaDex, Inc. Currently, he serves as Chairman and member of the Board of Directors at public biotech companies such as BiondVax Pharmaceuticals Ltd. and Pluristem Therapeutics Inc.
"I've worked with quite a few management teams in young companies over the years who have been quite successful, and I find the team at Lunit to be among the best," said Mark. "They are smart, mature, understand their company, their customers and, most importantly, how they can make a meaningful impact on the lives of the cancer patients they serve. I believe they are poised to build a great company and play a significant role in the diagnosis and treatment of cancer, and it's a pleasure to be working with them."
Dr. Young Kwang Chae
Dr. Young Kwang Chae is a medical oncologist at Northwestern University Feinberg School of Medicine, also a Co-Director of Developmental Therapeutics Lurie Cancer Center of Northwestern University. Dr. Chae has published more than 110 peer-reviewed journals and been involved in more than 115 research abstracts on personalized precision medicine and novel combination therapy. From 2020, he engaged with the Lunit research team to validate the predictive power of AI-based immune phenotype, and the study was presented at ASCO 2020.
"I am looking forward to fulfilling the dream of providing cancer patients with the immunotherapy and customized treatment they need," said Dr.Chae. "I believe Lunit's AI technology will serve as a stepping stone to complete customized immunotherapy."
"We started off as a software company mainly focused on research and development. In the past few years, we have successfully launched and commercialized our early products with global business partners, growing to become a leading medical AI provider," added Suh. "There is still much more to come and with the help of our new multidisciplinary experts, we will be able to take a step further towards conquering cancer through AI."
Lunit wins Tumor Proliferation Assessment Challenge (TUPAC) 2016
Lunit to unveil data-driven imaging biomarker at RSNA 2016
Lunit to showcase AI-powered products at USCAP 2017
Lunit INSIGHT: The First-ever, Real-time Imaging AI Analytics on the Web
Lunit Returns to RSNA with Real-time Imaging Platform, Featuring Cloud-based A
Lunit Unveils “Lunit INSIGHT,” A New Real-time Imaging AI Platform on the Web at RSNA 2017
Lunit INSIGHT: Q&A with Brandon B. Suh, Chief Medical Officer at Lunit
ANNOUNCING: BRANDON SUH, OUR NEW CEO
Lunit preps Korean IPO led by NH Investment Bank
Media Advisory: Lunit at RSNA 2018
Lunit Brings its Newest AI Solution for Mammography to RSNA 2018
Lunit Partners with Fujifilm and Salud Digna to Provide Medical AI Solution in Mexico
Lunit announces new members in its advisory board: Dr. Eliot Siegel, Dr. Linda Moy, and Dr. Khan Siddiqui
Lunit to Introduce Medical AI Solutions at GTC 2019
Lunit to Present Abstracts on AI-powered Precision Pathology at 2019 AACR Annual Meeting
Lunit to Showcase AI Solution for Breast Cancer at SBI 2019
Lunit to Present Findings on the Predictive Power of AI Biomarker for Lung Cancer Immunotherapy at ASCO 2019
Lunit Receives Korea MFDS Approval for its AI Solution for Breast Cancer, Lunit INSIGHT MMG
Lunit Named to the 2019 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups
Lunit Gets Korea MFDS Approval for its AI Solution for Chest X-ray, Lunit INSIGHT CXR 2
Lunit at RSNA 2019
Lunit Announces its First CE Mark for AI-Powered Chest X-ray Analysis Software, Lunit INSIGHT CXR
Lunit AI software clinically installed in global sites—to be presented at RSNA 2019
Lunit Secures $26M in Series C Funding Round, Led by Asian Investors
AI-assisted Radiologists Can Detect More Breast Cancer with Reduced False-positive Recall
Renowned Oncologist Dr. Tony Mok Joins Lunit Advisory Board
Lunit Releases Its AI Online to Support Healthcare Professionals Manage COVID-19
Lunit to Present Findings on the Predictive Power of AI-based Analysis of Immune Phenotype at ASCO 2020
Lunit INSIGHT MMG, an AI Solution for Breast Cancer Detection, Now CE Certified
AI Solution for COVID-19, Developed by Medical AI Firm Lunit, Now Has Users in More Than 10 Countries
Lunit Awarded as Technology Pioneer by World Economic Forum
Lunit at ECR 2020: Providing Virtual Exhibition and Online Presentations
Lunit Named to the 2020 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups
Emergent Connect Partners with Lunit to Provide Cloud Based AI Solutions
AI Analysis Can Improve Lung Cancer Detection on Chest Radiographs
AI has Added Value in Insurance Underwriting Process, Recent Pilot Project Between Lunit and Cathay Financial Innovation Lab Reveals
RSNA 2020--Lunit Collaborates with Global Giants in Presenting its AI Solution at Virtual Booths of GE Healthcare, FujiFilm, and Sectra
AI Proves Its Value in Assistance for Emergency Cases-- With Higher Accuracy and Timely Reporting Time of Chest Radiographs
Lunit Expands Collaboration with GE Healthcare to Advance AI Adoption across Healthcare Industry
AI Can Offer Fast and Reliable Examination to Triage COVID-19 Patients-- A Multicenter Retrospective Study Reveals
Recent Studies Reveal High Performance of Lunit AI in Breast Cancer Detection
South Korean Medical AI Provider and PACS Leader Enters Indonesian Market, to Help COVID-19 Screening and Diagnosis
Lunit Presents AI-powered Pathologic Classification of Immune Phenotype that Predicts Response to Immunotherapy at USCAP 2021
AACR 2021 - Lunit Presents Abstracts Demonstrating the Potential of its AI Biomarker in Cancer Treatment
Will AI Identify Breast Cancer Better Than Radiologists in Actual Clinical Screening?
AI-based Analysis of Cancer Tissue Predicts Response to Immunotherapy--Findings to Be Presented at ASCO 2021
Clinical Application of Lunit AI For Chest Radiography and Mammography to Be Presented at AOCR 2021
Lunit Secures $26M Investment from Guardant Health in a Strategic Funding Round
A Multi-reader Study Finds Unnecessary CT Exams Can Be Reduced by 30% When Analyzing Chest Radiographs with AI
Fujifilm Introduces its AI-powered Product for Chest X-ray in Japan, in Collaboration with Lunit
Lunit Collaborates with Intel to Provide AI Solutions to CPU-Based Customers in Need of Effective X-ray Diagnosis
Lunit AI Applied to Clinical Trial for Drug Development for the First Time--Findings Presented at ESMO 2021
Lunit to Participate in RSNA 2021, Presenting its New AI Solutions for Digital Breast Tomosynthesis and Chest CT
RadLink, Singapore’s Leading Imaging Center, Adapts Lunit AI to Analyze Chest X-rays and Mammograms
Lunit Presents Studies at SITC 2021, Highlighting the Effectiveness of AI in Predicting Response to Immunotherapy in a Clinical Trial Setting
Lunit Gets FDA Nod for AI-based Chest X-ray Triage Solution, Developed for Sorting of Emergency Cases
Lunit's AI Software for Breast Cancer Detection, Lunit INSIGHT MMG, Wins FDA Clearance
Research Backs Clinical Efficacy of Lunit's Radiology AI Products; Abstracts to be Presented at RSNA 2021
Medical AI Provider Lunit Raises $61M in Funding Round Led By Major Global Healthcare Investors
Lunit Named to the 2021 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups
Lunit Obtains MDSAP Certificate, Granted Fast-Track Regulatory Process in Major Countries
Lunit to Showcase Chest and Breast Radiology AI in Arab Health 2022
Breakthrough Study Validates Artificial Intelligence as a Novel Biomarker in Predicting Immunotherapy Response - Published in Journal of Clinical Oncology
Medical AI Startup Lunit gets Preliminary Approval to go Public on KOSDAQ
Lunit AI solution for PD-L1 expression analysis receives CE mark
Lunit AI Biomarker PD-L1 Demonstrates Clinical Efficacy as Diagnostic Aid in Cancer Treatment–Published in the European Journal of Cancer